




Cardio IQ®

Uncover Hidden Risk
for Heart Attack and Stroke

Cardio IQ NT-proBNP–91739(X) Identifying patients at risk for heart failure (HF)



The Cardio IQ
NT-proBNP biomarker
provides insight
beyond the diagnosis¹
of heart failure

Cardio IQ NT-proBNP is a powerful, independent* and more precise **predictor of the risk** for HF or cardiovascular death in patients with CHD²

- Multiple large studies prove patients who have stable and unstable coronary heart disease, plus elevated NT-proBNP, have increased risk of heart failure, mortality, stroke, and cardiovascular events³⁻⁶

* Independent of other risk factors including Left Ventricular Ejection Fraction, NYHA clinical HF grade, markers of kidney dysfunction, hypertension, smoking, and other biomarkers such as hs-CRP and ST2



Cardiovascular patients who may benefit from earlier identification of risk:

- Low-risk, stable CHD patients with normal left ventricular function



Individualized risk information provided by gender-based cut points:

Heart Failure Risk Associated with NT-proBNP in Patients with Coronary Heart Disease³

Risk Category ^a	Men (pg/mL)	Women (pg/mL)
Optimal	<253	<372
High risk	≥253	≥372

^a Risk of heart failure, stroke, and cardiovascular-associated mortality

Cardio IQ NT-proBNP Result Interpretation³

4X the risk for fatal and non-fatal HF for CHD patients

Test Name	Test Code	CPT Code*
Cardio IQ NT-ProBNP	91739(X)	83880

* The CPT codes provided are based on AMA Guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.



For more information, including other cardiometabolic testing, contact your Quest Diagnostics representative or visit us at QuestDiagnostics.com/Education and 4myheart.com

References:

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2013;128:e240-e319. doi:10.1161/CIR.0b013e31829e8776.
2. Mishra RK, Beatty AL, Jaganath R, et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. *J Am Heart Assoc*. 2014;3:e000907. doi: 10.1161/JAHA.114.000907.
3. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. *J Am Coll Cardiol*. 2007;50:205-214.
4. März W, Tiran B, Seelhorst U, et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. *Clin Chem*. 2007;53:1075-1083.
5. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. *J Am Coll Cardiol*. 2006;47:552-558.
6. Omland T, Richards AM, Wergeland R, et al. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. *Am J Cardiol*. 2005;95:24-28.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks – ® and ™ – are the property of their respective owners. © 2016 Quest Diagnostics Incorporated. All rights reserved. MD74 09/2016

